Background: Ovarian cancer is the major cause of death from gynecological malignancy with a 5 year survival of only ~30% due to resistance to platinum and paclitaxel-based first line therapy. Dysregulation of the PI3K/mTOR and RAS/ERK pathways is common in ovarian cancer, providing potential new targets for 2 nd line therapy.
Introduction
Ovarian cancer has the highest mortality rate among all gynecological cancers
(1) largely due to the late diagnosis. Most patients respond to debulking surgery and treatment with a combination of taxane and platinum-based therapy, but later develop disease recurrence due to intrinsic and acquired resistance. Thus novel strategies are required to better treat this disease at diagnosis and/or provide an effective second line treatment. Dysregulation of both the PI3K pathway and RAS/ERK pathway are highly prevalent in all histotypes of ovarian cancer and hence targeting these pathways may provide a novel alternative to conventional therapy. (2) (3) (4) (5) PI3K initiates a signalling cascade that activates mTORC1 via AKT and subsequent phosphorylation of many factors that impact on cell metabolism, angiogenesis, cell growth, proliferation and survival. (6) (7) (8) RAS signalling via RAF and MEK leads to the activation of both extracellular signal-related kinase (ERK) 1 and ERK2. ERK phosphorylates several cytosolic and nuclear proteins, including transcription factors that regulate the cell cycle. (9) Currently, inhibitors of RAF and MEK are the most advanced in the clinic for blocking ERK signalling, (10, 11) while for the PI3K pathway there are many agents targeting different members of the pathway (PI3K, AKT, mTORC1, mTOR) including some that inhibit multiple components (PI3K and mTOR). (12) The dual PI3K and mTOR inhibitors have shown great promise in preclinical models. (13) PF-04691502 (PF502) is an ATPcompetitive inhibitor of PI3K and both mTOR complexes (14) and is currently in several clinical trials (15) , PD-0325901 (PD901) is a selective inhibitor of both MEK isoforms (MEK1/MEK2) and thus prevents activation of ERK and is also currently in a clinical trial. (16) Given the high frequency of activating events in both the PI3K and RAS pathways we sought to determine the efficacy of PF502 and PD901 on a panel of 30 ovarian tumour cell lines. In addition, we performed global mRNA expression profiling, complemented with targeted mutation and pathway activity analysis to identify potential predictive and response biomarkers. These analyses identified RAS signalling as a key mediator of PF502 resistance and established the rationale for combination therapies with PF502 and PD901 in ovarian cancer.
Materials and Methods

2.1.Cell Lines
Individuality of ovarian cell lines listed in Supplementary Table S1 was routinely confirmed by a PCR based short tandem repeat (STR) analysis using 6 STR loci.
2.2.Therapeutics
2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-
methylpyrido [2,3-d] pyrimidin-7(8H)-one (PF-04691502) (14) and
N-[(2R)-2,3-
dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4iodophenyl)amino]-Benzamide (PD-0325901) (17, 18) were obtained from Pfizer Oncology.
2.3.Cell Proliferation Assay
Cells were drug treated for 72hrs, and cell number assessed via an imaging system (Incucyte, Essen Instruments) or the sulforhodamine B assay; cells were less than 90% confluent in control wells at the end of incubation. GI50 was determined using GraphPad Prism. For PF502, GI50 values followed a Gaussian distribution so the mean (232nM) of all 30 cells was used to define cells as resistant or sensitive. For PD901, as the GI50's did not follow a Gaussian distribution the geometric mean (1.21 µM) was used to define cells as resistant or sensitive.
To assess drug synergy dose response curves were generated for both single agents and their combination. A mutually nonexclusive combination index (CI) was determined using CalcuSyn (Biosoft) where: CI<1 synergy; CI>1 antagonism; CI=1 additive.
The combination ratio was fixed and based on the GI50 for each drug, where the highest and lowest combination ratio was 8 times and 1/8th the GI50, respectively. Cell lines resistant to PD901 were treated with a fixed concentration of 100nM PD901 in combination with a dose range of PF502.
2.4.Cell Death Assay
Cell death was determined using propidium iodide (PI) staining followed by flow cytometry (LSRII) and data analyzed using FCS express software (De Novo Software).
2.5.Immunoblotting
Cells were lysed in RIPA buffer, subjected to SDS-PAGE, immunoblotted, and protein bands visualized and quantified (ImageQuant :GE Healthcare: Supplementary Methods) .
2.6.Gene Expression
Cells were harvested at 50-80% confluency. RNA was extracted (QIAGEN RNeasy kit), in vitro transcribed and biotin labelled cRNA was fragmented and hybridized to Affymetrix 1.0ST expression array as per manufacturer's instructions (accession number GSE43765).
Differential gene expression was determined using the Limma R package after RMA normalization and background correction. (20) Genes that had a >1.4 fold change in expression between resistant and sensitive were included in the MetaCore pathway analysis (http://thomsonreuters.com/metacore).
2.7.Gene Mutational Analysis
Genomic DNA was extracted using the QIAamp DNA Blood Mini kit (QIAGEN). PCR primers and annealing temperatures are in Supplementary Table S2 . Cycle sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit and analyzed on a 3130 Genetic Analyzer (Applied Biosystems).
2.8.Human Ovarian Cancer Xenograft Assays
Female Balb/c nude mice were injected subcutaneously with 5x10 6 cells in 0.05mL of 50%
Matrigel. When tumours reached ~100mm 3 , mice were randomized into groups of 10 and daily oral gavaged with vehicle, 10mg/kg PF502, 1mg/kg PD901 or PF502 plus PD901.
For immunoblotting, tumours were frozen and protein extracted from 4 mice, 4hrs after a single drug treatment.
2.9.Gene Set Enrichment Analysis
For Gene Set Enrichment Analysis (GSEA) 1,000 iterations were performed using the default weighted enrichment statistic and a signal-to-noise metric to rank genes based on their differential expression across sensitive and resistant cell lines.
2.10.Statistical Analysis
Student's t-test or one-way analysis of variance followed by Tukey's Multiple Comparison
Test was performed using GraphPad PRISM. To calculate the correlation between two variables a two-tailed Spearman correlation test was performed. Chi-square tests were used to assess associations between mutation status and sensitivity. Differences of p<0.05 were considered significant. All data are expressed as mean + SEM.
Results
3.1.PF502 and PD901 inhibit ovarian cancer cell proliferation
The PF502 concentration, that inhibited proliferation by 50% (GI50) ranged from 16nM to 640nM (Fig. 1A ) whereas response to PD901 showed a bimodal pattern, with a subset of cells that were highly sensitive (GI50's 3nM to 300nM: Fig. 1B ). All cell lines showed sensitivity to at least one of the two agents.
3.2.PF502 and PD901 induces cell death
PF502 induced cell death in all cell lines and significantly correlated (Spearman correlation test r = -0.66, p<0.0001) with the drugs ability to inhibit cell proliferation (Fig. 1C) . In contrast, in PD901 sensitive cells there was minimal cell death and even less in resistant cell lines (Fig. 1D ).
3.3.PF502 inhibits PI3K/AKT/mTOR pathway signalling
To assess if PF502 was effectively inhibiting its targets a subset of sensitive and resistant cell lines were treated with either 100nM or 1µM PF502 and phosphorylation of components of the PI3K/mTOR pathway measured. Phosphorylation of PRAS40 (P-PRAS) was used as a measure of AKT activity, P-AKT (S473) as a measure of AKT and mTORC2 activity, and both P-rpS6 and P-4EBP1 as a measure of mTORC1 activity. At 100nM, PF502 decreased the phosphorylation of all proteins measured and was a highly potent inhibitor of AKT phosphorylation in PF502 sensitive compared to resistant cell lines (Fig. 2) . The response to PF502 in resistant cell lines of all phospho-proteins measured was less robust indicating that resistance is associated with the inability of PF502 to effectively inhibit PI3K/AKT/ mTORC1 signalling.
3.4.PD901 effectively inhibits MEK activity in resistant and sensitive cells.
To assess if PD901 effectively inhibited MEK activity we treated cells with either 100nM or 1µM PD901 and determined phosphorylation of ERK (P-ERK) in a subset of resistant and sensitive cell lines. P-ERK was completely inhibited with 100nM PD901 in both resistant and sensitive cell lines (Fig. 3) , demonstrating that drug resistance was not due to failure to inhibit MEK.
3.5.PI3K & RAS/ERK pathway analysis in ovarian cancer cell lines
To evaluate if the activation state of PI3K or RAS/ERK pathways influence ovarian cancer cell sensitivity to PF502 and/or PD901 we determined PTEN protein levels, activating mutations in PIK3CA, AKT1, BRAF and KRAS genes and then correlated these results with sensitivity to the inhibitors. 25 cell lines (83%) expressed <50% PTEN protein compared to HOSE ( PI3K and RAS/ERK pathway activation was further assessed by measuring P-PRAS40, PrpS6 and P-ERK (Fig. 4B ). P-PRAS40 was elevated in 16 (53%) of ovarian cancer cell lines, however, consistent with the genomic analysis, there was no correlation with P-PRAS levels and sensitivity to PF502 or resistance to PD901, suggesting that elevated AKT activity does not affect sensitivity to either of these inhibitors. Importantly however, increased P-rpS6 levels and P-ERK correlated with resistance to PF502 (p< 0.02, Spearman test: Supplementary Fig.S1 ).
3.6.Differential gene expression between PF502 and PD901 resistant and sensitive cell lines
To identify molecular pathways that may confer sensitivity and/or resistance to either PF502 or PD901 we examined the difference in gene expression between resistant and sensitive cell lines using GSEA and MetaCore pathway analysis. Using GSEA two RAS oncogenic signatures and a "basal" breast cancer phenotype, which is characterized by RAS/ERK activation were enriched in PF502 resistant cell lines (Supplementary Table S3 ).
(23) In contrast, RAS oncogenic signatures and the "basal" breast cancer phenotype, were highly represented in PD901 sensitive cells (Supplementary Table S4 ). Metacore analysis of differentially expressed genes was also indicative of RAS/ERK activation in PF502 resistant and PD901 sensitive cells, consistent with the GSEA. Furthermore, Metacore analysis implicated cytokine signaling as potentially conferring PF502 resistance, which also may reflect RAS/ERK activation (24) (Supplementary Table S5 ). These data support the mutational and western analysis that increased signalling in the RAS/ERK pathway correlates with PF502 resistance and PD901 sensitivity. This data suggests that in ovarian cancer cells increased RAS/ERK signalling confers sensitivity to PD901 and reinforces the possibility that PD901 may prove effective in inhibiting the growth of PF502-resistant cell lines.
3.7.PD901 and PF502 synergize in PF502 resistant cell lines
Our protein, mutation and gene expression data all strongly indicate that activation of the RAS/ERK pathway conferred resistance to PF502. Thus we investigated whether dual inhibition of MEK and PI3K/mTOR activity resulted in greater inhibition of proliferation and/or cell death compared to single agent treatment. In 5 of 6 PF502 resistant cell lines a combination of PF502 and PD901 resulted in a synergistic reduction in cell proliferation (mutually nonexclusive CI<1) whilst the other an additive response (CI=1). Importantly, in two PF502 and PD901 resistant cell lines (SKOV3 and JHOC5) there was a robust synergistic response (Fig.5) .
3.8.Pre-clinical efficacy studies
To confirm that resistance to PF502 and the synergistic effect with PD901 was relevant in vivo, we tested anti-tumour effects in xenografts. ES2 tumours were relatively resistant to PF502 with a small (17+3%) but significant decrease in tumour size following 19 days of treatment, more sensitive to PD901 (37+3% decrease) and more potently inhibited when these compounds are combined (75+3% decrease: Fig.6 ). Levels of P-AKT were barely detectable in ES2 xenografts, consistent with cell culture data (Fig 2A) however P-PRAS was effectively inhibited by PF502. Importantly PD901 was more effective than PF502 at inhibiting P-rpS6 and the combination was more effective than single agent treatment.
Thus decreased P-rpS6 reflected inhibition of tumour growth and that RAS/ERK pathway induced P-rpS6 (25) is associated with PF502 resistance.
In a second human xenograft model using MCAS cells, which in vitro were relatively resistant to PF502 but sensitive to PD901, PF502 alone significantly inhibited tumour growth with a 68+3% decrease in tumour size following 19 days of treatment (Supplementary Figure S2) . Western analysis demonstrated that PF502 not only decreased PI3K/mTOR signaling (decreases in P-AKT, P-PRAS and P-S6) but also decreased P-ERK, supporting the hypothesis that inhibition of both PI3K/mTOR and the MAPK/ERK pathways effectively inhibits ovarian tumour growth.
Discussion
Both the PI3K/mTOR and RAS/ERK pathways are highly dysregulated through gene amplifications, gene deletions (2) and mutations in all histotypes of ovarian cancer. response. Mutations in PIK3CA and loss of PTEN predict sensitivity to PI3K pathway inhibitors in most (27) (28) (29) , but not all cases (30) and this may reflect differences in the genetic backgrounds of the tumour cells and/or the specificity of the individual inhibitors. In contrast, mutations in KRAS and BRAF did confer sensitivity to MEK inhibition by PD901, and furthermore GSEA also identified activation of the RAS pathway as conferring sensitivity. This is consistent with previous studies that demonstrated that mutations in KRAS and BRAF confer sensitivity to MEK inhibition in several different cancer types (31) (32) (33) including ovarian.
Identification of predictors of drug resistance will be essential for optimizing treatment regimes. Our analysis focused on signatures of resistance to PF502 given its potency in inhibiting growth of the majority of cell lines. Protein, mutational and genomic analysis implicated activation of the RAS/ERK pathway as conferring PF502 resistance, consistent with similar findings in other systems. (28, (35) (36) (37) This resistance is likely due to known effects of the RAS/ERK pathway on rpS6 phosphorylation, translation (25) , gene transcription and cell cycle progression.
(38) Strikingly, in combination experiments the majority of PF502 resistant cell lines showed a synergistic response when treated with both PF502 and PD901 and this was also evident in vivo in the ES2 xenograft model. Importantly, in those cell lines that were resistant to both PF502 and PD901 individually, the combination potently inhibited cell growth. These data suggest that while PI3K/mTOR signalling is vital for ovarian cancer cell proliferation, optimal inhibition of tumour growth will require targeting the PI3K/mTOR and RAS/ERK pathways in combination. Indeed, xenograft studies with the MCAS cell line that was PF502 resistant but PD901 sensitive, revealed in vivo sensitivity to single agent treatment with PF502 that correlated with additional inhibition of the RAS/ERK pathway.
P-rpS6 level reflected PF502 efficacy in cell lines and in vivo efficacy of PF502, PD901
and their combination, thus is a potential tumor response biomarker. The failure of PF502 to effectively inhibit AKT or mTORC1 activity in resistant cell lines requires further investigation. Cellular availability of PF502 is unlikely the cause as it is not a substrate for the multidrug resistance protein 1, is not rapidly metabolized (39) and our pathway analysis reveals that in some resistant cell lines the drug is able to effectively inhibit one target but not another. A more likely explanation is that other pathways feed into the PI3K pathway, such as RAS/ERK or DNA-dependent protein kinase both of which can phosphorylate components of the PI3K pathway leading to its activation. (25, 40) In summary, the majority of ovarian cancer cell lines responded to the PI3K/mTOR inhibitor, PF502 making this a potential novel treatment for ovarian cancer. In contrast, the obvious dichotomy in response to MEK inhibition by PD901 and the correlation of Mol Cancer Ther. 2010; 9:1985 -1994 .
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